Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback